



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Understanding which technologies are coming into the healthcare systems

3rd Industry Stakeholder Platform on R&D support, 18 May 2018

Presented by Michael Berntgen (EMA) in collaboration with Claudia Furtado and Ingvil Von Mehren Sæterdal (representing EUnetHTA) as well as Ad Schuurman, Wytse Bruinsma and Niels Speksnijder (ZIN)

An agency of the European Union





Identifying technologies that are coming into the healthcare systems

Different elements are taken into consideration for the approach to horizon scanning:

- Objectives / desired impact
- Scope of technologies / interventions
- Observation period (“distance to horizon”)
- Data sources and detection methodology
- Triage
- Reporting mechanisms



Decision makers use different methodologies and for various purposes



Reference points for collaboration on “Horizon Scanning”

- HTA Network Reflection Paper on [“Synergies between regulatory and HTA issues on pharmaceuticals”](#)


3. Collaborate on the identification of therapeutic areas for which the medical need has not been sufficiently met yet and on the identification of emerging medicines through horizon scanning programmes for sharing early information, defining clear evidence requirements, and for identifying needs for further evidence generation (e.g. development and validation of patient reported outcomes).

- [EMA-EUnetHTA work plan 2017-2020](#)

- Explore opportunities to collaborate on monitoring of new medicines’ approvals (“horizon scanning”)


- [EMA – Payer Community meeting](#)

In conclusion, part of the data needs identified by payers can be addressed already through publicly available information; emphasis would be on exploring ways to optimise the reporting. Furthermore, there are potential benefits by leveraging learning from performing business pipeline monitoring; also there might be opportunities to explore how data held by different actors may become mutually beneficial. It would be important to avoid duplication of efforts hence there is a need to link up with other initiatives on European level. The next step will therefore be to broaden this discussion to also include EUnetHTA and to jointly address the actions listed above.



Objectives with business analysis and forecasting

- To support planning for “the near future” (operational workload, expertise needed) based on type of applications, therapeutic areas, medicinal products, indications etc.
- To detect early important (and potentially “disruptive”) technologies with impact on public health
- To facilitate development activities by identifying ‘road blocks’, signpost companies to interaction opportunities and support reviews of trends
- To support topic identification selection and prioritisation
- For payers: to support policy decisions for national markets (e.g. www.Horizonscangeneesmiddelen.nl)





Opportunities for collaboration across decision makers in the “horizon scanning” space

Products under regulatory assessment

- Improved reporting on regulatory milestones incl. relevant data fields to inform subsequent decision makers
- Optimise regulatory assessment reports for subsequent use by HTAs and payers (e.g. clarity and completeness)



Products to be submitted for assessment by decision makers

- Mapping of existing and planned horizon scanning activities
- Explore opportunities to make pre-submission information available incl. feasibility to increase predictability of upcoming submissions



The wider horizon – products in development and beyond

- Collaboration in the context of strategic initiatives
- Use of available information on regulatory development support by HTAs and payers
- Contribution to discussions on unmet medical need

